Roche Jumps Into Mergers and Acquisitions With $1.7 Billion Deal
On the heels of Bayer AG (NASDAQOTH: BAYRY) licensing Loxo Oncology's (NASDAQ: LOXO) fusion-targeting cancer drug, Roche Holdings (NASDAQOTH: RHHBY) is acquiring Ingynta (NASDAQ: RXDX), a company that's also exploring origin agnostic approaches to cancer treatment. The $1.7 billion all-cash deal reflects growing excitement in this promising area of cancer research and development.
Historically, cancer treatment has been driven by the origin of the cancer (e.g. breast cancer, lung cancer, or kidney cancer). In the future, it may be driven by discoveries at the molecular level.
Image source: Getty Images.
Source: Fool.com
